



<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 2488.031		APPLICATION NO. <b>107560727</b>	
				Shai et al.		<b>IAP9 Rec'd PCT/PTO 14 DEC 2005</b>	
				FILING Herewith		GROUP ART Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AG	5,871,746	02/16/1999	Boutillon et al.	424	208.1		
AH	5,837,249	11/17/1998	Heber-Katz et al.	424	186.1		
AI	5,583,198	12/10/1996	Whittaker	530	345		

U.S. PATENT APPLICATION PUBLICATIONS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	


  

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	












EXAMINER 	DATE CONSIDERED <b>1-9-08</b>
--	-------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Supplementary Information Disclosure Citation</b>  <b>List of references cited by Applicant</b>  (Sheet 1 of 2)	Attorney Docket Number	Application Number <b>10/560,727</b>
	Applicant: <b>Yechiel et al.</b>	
	Filing Date <b>14 December, 2005</b>	Group Art Unit

U.S. PATENT DOCUMENTS							
*Examiner Initial		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						

FOREIGN PATENT DOCUMENTS								
*Examiner Initial		DOCUMENT NUMBER	ISSUE DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1							

*Examiner Initial	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	C1	ALEXANDER ET AL., "Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches". Drugs. 1997 Nov;54(5):657-78.
	C2	AVRAHAMI ET AL., "Effect of multiple aliphatic amino acids substitutions on the structure, function, and mode of action of diastereomeric membrane active peptides". Biochemistry 2001 October 23;40(42):12591-603.
	C3	AVRAHAMI ET AL., "Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity". Biochemistry 2002 Feb 19; 41(7):2254-63.
	C4	BECHINGER, "The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy". Biochim Biophys Acta. 1999 Dec 15;1462(1-2):157-83.
	C5	DENNING DW. "Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host". J Antimicrob Chemother. 1991 Oct;28 Suppl B:1-16.
	C6	EFRON ET AL., "Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture". J Biol Chem. 2002 Jul 5;277(27):24067-72. Epub 2002 Apr 5.
	C7	GAVISH ET AL., "Growth inhibition of prostate cancer xenografts by halofuginone". Prostate. 2002 May 1;51(2):73-83.
	C8	GROLL ET AL., "Trends in the postmortem epidemiology of invasive fungal infections at a university hospital". J Infect. 1996 Jul;33(1):23-32.
	C9	HONG ET AL., "Structure and organization of hemolytic and nonhemolytic diastereomers of antimicrobial peptides in membranes". Biochemistry. 1999 Dec 21;38(51):16963-73.
	C10	MERRIFIELD, "Solid phase peptide synthesis". J. Am. Chem. Soc. 1963 January 31; 85: 2149-2154
	C11	MINAMOTO ET AL., "Fungal infections in patients with acquired immunodeficiency syndrome". Med Clin North Am. 1997 Mar;81(2):381-409.
	C12	OREN ET AL., "Selective lysis of bacteria but not mammalian cells by diastereomers









37 CFR 1.501

Docket no.

Applicant: Yechiel et al.

Application no. 10/560727

Information Disclosure Citation  
in a Patent  
(Sheet 2 of 2)

		of melittin: structure-function study". Biochemistry. 1997 Feb 18;36(7):1826-35.
	C13	OREN ET AL., "A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity". J Biol Chem. 1997 Jun 6;272(23):14643-9.
	C14	OREN ET AL., "Mode of action of linear amphipathic alpha-helical antimicrobial peptides". Biopolymers. 1998;47(6):451-63.
	C15	PAPO ET AL., "A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice". J Biol Chem. 2003 Jun 6;278(23):21018-23. Epub 2003 Mar 19.
	C16	SHAI ET AL., "Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides". J Biol Chem. 1996 Mar 29;271(13):7305-8.
	C17	TOSSI ET AL., "Amphipathic, alpha-helical antimicrobial peptides". Biopolymers. 2000;55(1):4-30.
	C18	TSUBERY ET AL., "Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria". J Med Chem. 2000 Aug 10;43(16):3085-92.
	C19	UNGER ET AL., "The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: implication to their mode of action". Biochemistry. 2001 May 29;40(21):6388-97.
	C20	WALSH ET AL., "Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients". Infect Dis Clin North Am. 1996 Jun;10(2):365-400.
EXAMINER	David Kaban	
	DATE CONSIDERED	1-9-08